Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial
Objective: To assess amantadine effects on dyskinesia and other PD symptoms when adjunct to L-DOPA in early PD. Background: Amantadine is efficacious on L-DOPA-induced dyskinesia…Therapeutic effects of citral nanoliposome on Parkinson’s treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways
Objective: The present study aimed to assess the effects of citral nanoliposome on Parkinson's treatment in a rat model. Background: Parkinson's disease is the most…Dopamine transporter in the brain is linked to irritable bowel syndrome in Parkinson´s disease
Objective: To assess correlations between gastrointestinal symptoms and dopamine transporter (DAT) changes in striatal and extrastriatal areas in Parkinson´s disease (PD) patients. Background: Gastrointestinal symptoms…Clinic versus home dose optimization of apomorphine sublingual film in Parkinson’s Disease: cross-study comparison of safety
Objective: To compare the safety profile of clinic versus home dose optimization of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease experiencing OFF episodes.…Psychosocial factors impacting participation in a time-intensive deep brain stimulation study of individuals with Parkinson’s disease and dystonia
Objective: To evaluate psychosocial factors impacting the number of hours of participation in the first five months of a time-intensive deep brain stimulation (DBS) study.…Building a consensus conceptual model of meaningful symptoms and impacts in early Parkinson’s disease
Objective: To develop a consensus based conceptual model of meaningful symptoms and impacts in early Parkinson’s disease (PD) through aligning of PD qualitative research carried…Operationalising goal setting as an outcome measure: Experience from the PRIME-UK randomised controlled trial
Objective: To select a suitable primary outcome for the evaluation of a multicomponent intervention for people with parkinsonism. Background: The multicomponent PRIME model of care,…Effects of GBA1 mutations and STN-DBS on response inhibition in Parkinson’s disease
Objective: To determine specific pattern of cognitive dysfunction in Parkinson’s disease (PD) patients who are glucocerebrosidase mutation carriers (PD-GBA1) compared with non-mutation carriers with and…Are GBA–Parkinson Disease patients’ good candidates for Deep Brain Stimulation? A Longitudinal Multicentric study on a Large Italian Cohort
Objective: To investigate the impact of GBA variants on the long-term outcome of deep brain stimulation (DBS) in a large cohort of Italian PD subjects…Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.
Objective: Istradefylline is FDA approved for use in patients with PD treated with carbidopa-levodopa to reduce off time. GUH Movement Disorder Group has observed that…
- « Previous Page
- 1
- …
- 191
- 192
- 193
- 194
- 195
- …
- 436
- Next Page »